Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6738037 | 0.92 | CHRNA7 (0.47) | KCNH2KMT2AMCHR1ALDH1A1LMNA | |
| SCHEMBL7028528 | 0.89 | KMT2A (0.42) | KCNH2KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL7028529 | 0.89 | KMT2A (0.42) | KCNH2KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL7028336 | 0.88 | KCNH2 (0.47) | KCNH2KMT2AMCHR1ALDH1A1MEN1 | |
| SCHEMBL6622817 | 0.87 | LMNA (0.44) | KCNH2KMT2AMCHR1ALDH1A1LMNA | |
| SCHEMBL6739625 | 0.86 | POLB (0.48) | KMT2AMCHR1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL6738570 | 0.85 | L3MBTL1 (0.46) | KCNH2KMT2AALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL6736864 | 0.84 | KCNH2 (0.51) | KCNH2KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6738998 | 0.84 | KCNH2 (0.51) | KCNH2KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6738449 | 0.84 | KCNH2 (0.51) | KCNH2KMT2AALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ADRA1B, ADRB2, ADRA1D | KCNH2 13/4885KMT2A 3468/4885MCHR1 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.